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Abstract
Anaphylaxis is life-threatening and should be addressed urgently. Its treatment is not without side effects
and an accurate diagnosis must be made to prevent potential harm by the wrongful use of medication. A
46-year-old woman with hypertension treated with angiotensin converting enzyme inhibitor (ACEI) presented
to the emergency department with non-pitting oedema of the face and limbs. A hasty diagnosis of anaphylaxis
was made and intravenous adrenaline administered. The patient developed a myocardial infarction caused
by coronary artery spasm that required invasive intervention. The initial clinical picture was resolved when
the ACEI was discontinued unmasking a case of ACEI-induced angioedema. The correct differentiation of
these two apparently similar clinical entities is of utmost importance in the management of emergency
department patients.
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Introduction
Intramuscular adrenaline is the mainstay of treat-
ment of anaphylaxis [1]. The clinical diagnosis of this
entity can be challenging in the emergency setting and
can lead to the unnecessary use of this medication,
which may have dire consequences for the patients.
On the other hand, angiotensin converting enzyme
inhibitor (ACEI)-induced angioedema does not respond
to this kind of therapy and resolves with the disconti-
nuation of the causative drug [2]. The accurate diffe-
rentiation of these two entities is the key to the optimal
management of patients presenting to the emergency
department.
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Case report
A 46-year-old woman with hypertension, obesity
and smoking habits (20 pack-years), who was taking
perindopril 10 mg daily for about one year, presented
to the emergency department with swelling in the face
(mainly lips and eyelids), arms and hands, which had
woken her up from sleep at 5:00 AM. She also com-
plained of slight dyspnoea. Skin rash or pruritus were
not present. No causative agent for an allergic reaction
could be identified. At admission, non-pitting edema of
the face and upper limbs was noted. The patient had
stable vital signs and a normal cardiopulmonary
auscultation. She was medicated with 200 mg of hydro-
cortisone, 2 mg of clemastine and 1 mg of adrenaline
intravenously. Shortly after, she developed oppressive
chest pain and nausea, sinus tachycardia (150 beats
per minute), hypotension (arterial pressure of 60/27
mmHg), tachypnea (27 cycles per minute). An electro-
cardiogram (ECG) showed sinus rhythm and a 4 mm
ST-segment elevation in leads DII, DIII, V5 and V6
with reciprocal ST-segment depression in leads V1,
V2 and aVR (Figure 1). The echocardiogram revealed
good left and right ventricular function and hypokinesis
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Fig. 2. Coronary angiography showing an intermediate lesion in the distal right coronary artery (left) treated with stent placement (right)
Fig. 1. First ECG showing 4 mm ST-segment elevation in leads DII, DIII, V5 and V6 with reciprocal ST-segment depression in leads V1,
V2 and aVR (top), repeated after sublingual nitroglycerin with partial attenuation of the ST-segment elevation to 1.5 mm (bottom)
of the medio-basal inferior and lateral walls. 0.5 mg of
sublingual nytroglicerine was given and then repeated
5 minutes later with partial improvement in pain and
attenuation of the ST-segment elevation to 1.5 mm
(Figure 1).
She was transferred to our tertiary cardiology center
and submitted to a coronary angiography, which dis-
played an intermediate lesion in the distal right coronary
artery (Figure 2) that was quantified as a 78% stenosis
by intravascular ultrasound (IVUS) and had no signs
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of plaque instability. The lesion was treated with a drug
eluting stent (Figure 2).
Blood analysis was remarkable for a glycated hae-
moglobin of 5.2%, a C-reactive protein of 10.1 mg/L
(< 5.0 mg/L), a brain natriuretic peptide (BNP) of 122
pg/mL (< 100 pg/mL), a total cholesterol of 164 mg/
dL, an LDL-cholesterol of 104 mg/dL, an HDL-
cholesterol of 44 mg/dL, triglicerydes of 100 mg/dL, a
peak high-sensitive cardiac troponin I (hs-cTnI) of
5761.2 pg/mL (< 15.6 pg/mL) and a peak creatinine
kinase (CK) of 201 U/L (29-168 U/L). Imunoglobulline
E and complement fractions were within normal ranges.
Tryptase dosing was not performed. Before discharge,
the echocardiography revealed good left ventricular
function with no regional wall motion abnormalities and
the patient was discharged on acetylsalicylic acid, clopi-
dogrel, amlodipin and atorvastatin.
Discussion
This report illustrates a case of mismanagement
due to a series of mishaps – a diagnostic error, a proce-
dural error and a medication error – which resulted in
a serious consequence.
The diagnosis initially made was anaphylaxis, on
the count of the angioedema and the slight dyspnoea.
In fact, skin or mucosal involvement combined with
respiratory compromise is reason enough to suspect
anaphylaxis [1]. However, anaphylaxis is characterized
by a rapid onset, usually within two hours of exposure
to an allergen [1], and it is not possible to know in this
case how fast the onset was, since the patient was
asleep, or if there was an allergen involved, although it
is unlikely that the patient could have been exposed
during sleep. Nevertheless, in up to 20% of cases, the
allergen will not be identified [1].
Two kinds of acute myocardial infarction associated
with anaphylaxis are described, either caused by
coronary spasm, plaque erosion/rupture or stent throm-
bosis: Kounis syndrome which is caused by inflam-
matory mediators released from mast-cells and plate-
lets [3]; and adrenaline-induced myocardial injury
induced by the α1-adrenergic effect causing vasocon-
striction or the induction of platelet aggregation [4-13].
Taking into account the typical symptoms and ECG
changes occurring shortly after adrenaline injection,
coupled with a significant stenosis but with no signs of
plaque instability and the rise in troponin, it was
assumed that this was a type 2 myocardial infarction
(myocardial infarction secondary to an ischaemic im-
balance) due to coronary artery spasm [8] caused by
adrenaline.
Adrenaline should be administered to all patients
with suspected anaphylaxis or with features that could
evolve into anaphylaxis. The intramuscular route is
preferred because of its rapid onset of action and its
better safety profile. The recommended dose is 0.3
mg to 0.5 mg that can be repeated every 5 to 15 mi-
nutes if the response is suboptimal. Intravenous adre-
naline administration is only acceptable when there is
no response to intramuscular adrenaline and only by
strictly titrated infusion guided by close monitoring,
since most serious adverse reactions, such as acute
myocardial infarction, occur in this setting [1].
It is clear that the dose of 1 mg was excessive and
the route of administration was not adequate, and these
are probably the main responsible factors for the
development of vasospasm. However, cases of serious
cardiac events occurring after adrenaline adminis-
tration are being reported [6-9, 14], which emphasize
the potential hazards of this treatment. Hence, it could
be argued, that adrenaline administration should be
withheld unless patients are in a life-threatening
condition with clear evidence of cardiovascular or res-
piratory compromise, since the fatality rate is very low
and some milder anaphylactic reactions will resolve
spontaneously. Corticoids and anti-histamines can be
given in the meantime [15]. This patient complained
of mild dyspnoea which was interpreted as a sign of
respiratory compromise, but this could have been a
rushed assumption, since no wheezing or stridor were
present and the patient could have fared well without
adrenaline.
Importantly, the lack of skin rash or pruritus, which
are highly typical of allergic (histamine-induced)
angioedema, associated with the presumably not
sudden onset, the inability to identify an allergen and
the lack of evidence of an allergic reaction in the blood
work, puts the diagnosis of anaphylaxis into question.
ACEI-induced (bradikinin-induced) angioedema is
self-limiting, typically involves the face and upper limbs,
has a gradual onset and is not associated with rash or
pruritus. It is a very rare event in patients taking ACEI,
although it accounts for one third of angioedema cases
treated in emergency rooms, and is seldom life-threat-
ening. It can develop up to 10 years after initiation of
ACEI therapy. It does not require specific treatment,
adrenaline, corticosteroids and anti-histamines are inef-
fective and it resolves after drug discontinuation [2].
Although the diagnosis of both types of angioedema
relies on clinical features and no laboratory test can
provide undisputable proof, the diagnosis of anaphylaxis
can be supported by elevated serum tryptase within a
few hours after the start of the symptoms [1], which
unfortunately was not performed in this case. Never-
theless, for the reasons described above, it is the
authors’ opinion that this is a case of ACEI-induced
angioedema and not anaphylaxis as initially assumed,
which further adds to the wrongful use of adrenaline.
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Conclusion
Adrenaline is a very useful medication in cases of
life-threatening anaphylaxis, but is ineffective in ACEI-
induced angioedema. It is very important to distinguish
between these two types of angioedema in the
emergency department to avoid the wrongful use of
adrenaline, which is not without serious adverse events.
Since it is difficult to make this distinction, the correct
timing, dosage and route of administration of adrenaline
are the keys to avoid potential significant side effects.
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